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Background
Intranasal sprays must be delivered to the nasal cavity in
sufficient volume, appropriate viscosity and droplet size
and with a technique that allows optimal retention,
maximizes absorption from the mucosa, and the poten-
tial for maximum therapeutic effect. The aim of this
study was to evaluate nasal drug run-off after adminis-
tration of MP29-02* (a novel intranasal formulation of
azelastine hydrochloride (AZE) and fluticasone propio-
nate (FP) in an advanced delivery system) with sequen-
tial administration of marketed AZE and FP nasal sprays
in vitro.
Methods
A normal adult human nasal cavity in vitro model was
used [1,2]. A single spray of MP29-02* (0.137 mL
[137µg AZE/50µg FP]) or single sequential sprays of
AZE (0.137 mL) followed 1 min later by either branded
or generic FP (0.100 mL; i.e. multiple therapy) were
manually actuated into the model (away from the sep-
tum). A slight vacuum was applied during spray delivery
to simulate inhalation.
Results
Three replicates of MP29-02* showed no dripping or
back flow from the nasal cavity (i.e. anterior spray area
or anterior drip = 0.00 cm2). In all replicates MP29-02*
was observed to coat all turbinates up to the nasophar-
ynx, but not the nasopharynx structure itself. However,
three replicates of sequential sprays of AZE followed
1 min later by either branded or generic FP showed sig-
nificant anterior nasal drip (i.e. run-off) from the nostril
and also toward the back of the nasal cavity (i.e. poster-
iorly, which would be swallowed in vivo); AZE &
branded FP: anterior spray area = 1.67 – 3.16 cm2;
AZE & generic FP: anterior spray area: 0.68 – 1.83 cm2.
Conclusion
MP29-02* is a new AR treatment, comprising AZE and
FP in a single spray in an improved formulation and
device (vs marketed FP). In this model, the delivery of
MP29-02* showed improved retention in the targeted
areas compared to sequential administration of marketed
intranasal monoproducts. These could not be adminis-
tered together without run off (posteriorly and anteriorly)
which could diminish efficacy.
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